Effect of carnitine supplementation on clinical outcomes in patients with heart failure with preserved ejection fraction

Effect of carnitine supplementation on clinical outcomes in patients with heart failure with preserved ejection fraction - Effect of carnitine supplementation on clinical outcomes in patients with heart failure with preserved ejection fraction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011905

Enrollment

Registered

2013-09-30

Start date

2013-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with heart failure with preserved ejection fraction

Interventions

supplementation of L-carnitine control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with heart failure with preserved ejection fraction (LVEF = or over 45%) patients with carnitine deficiency defined as free carnitine level under 36micro mol/L or acyl carnitine/free carnitine ratio= or over 0.4

Exclusion criteria

Exclusion criteria: patients with acute coronary syndrome, severe valve disease, congenital disease,pulmonary thrombosis, and primary pulmonary hypertention

Design outcomes

Primary

Measure	Time frame
diastolic function assessed by echocardiography exerecise trelance	—

Secondary

Measure	Time frame
chanes in QOL Chanes in biomarker (BNP etc)	—

Countries

Japan

Contacts

Public ContactYoshiharu Kinugasa

Department of Molecular Medicine and Therapeutics, Tottori University Division of Cardiovascular Medicine

ykinugasa-circ@umin.ac.jp0859386517

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026